Processing Your Payment

Please do not leave this page until complete. This can take a few moments.

January 29, 2021

NH firm to market point-of-care COVID-19 antibody test

IMAGE | Pixabay.com
By Natalie Missakian

New Haven cancer diagnostics company Precipio Inc. said it has begun rolling out a newly authorized fingerstick COVID-19 antibody test developed by a Silicon Valley biotech.

The test can be administered in doctor’s offices and other point-of-care settings like nursing homes, urgent cares and pharmacies.

Precipio said Thursday that it signed a sales and distribution agreement with Palo Alto, Calif.-based Nirmidas Biotech Inc. to market its new test, which received emergency use authorization from the Food and Drug Administration in early January.

Called MidaSpot, the test uses a fingerstick blood test to detect antibodies against the RBD antigen on the surface of the SARS-CoV-2 virus, according to a news release. It yields results in 15 to 20 minutes.

Precipio said it has started rolling out the test to its existing oncology customer base and will “continue to expand into the market via additional sales channels.”

“We are excited to partner with Precipio to make our tests rapidly and widely deployed in the U.S. for point-of-care testing,” Nirmidas CEO Dr. Meijie Tang said in a statement. 

Antibody tests can determine if someone has already had the virus and has developed antibodies to fight it. They are not used to test for active infections.

Precipio said testing for antibodies offers “another important data point” for people who are weighing whether to be vaccinated against the virus.

“The FDA continues to demonstrate their willingness to expand the reach and usability of these tests, and we hope to soon see progress on the at-home testing front as well,” Precipio CEO Ilan Danieli said in a statement.  

Contact Natalie Missakian at news@newhavenbiz.com

Sign up for Enews

Most Recent

Most Recent

0 Comments

Order a PDF